Abstract
Past studies have shown that it has been difficult to discover and develop potent and selective κ opioid receptor antagonists, particularly compounds having potential for clinical development. In this study, we present a structure-activity relationship (SAR) study of a recently discovered new class of tetrahydroisoquinoline κ opioid receptor antagonists which led to (3 R)-7-hydroxy- N-{(1 S)-2-methyl-1-[(-4-methylpiperidine-1-yl)methyl]propyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (12) (4-Me-PDTic). Compound 12 had a Ke = 0.37 nM in a [35S]GTPγS binding assay and was 645- and >8100-fold selective for the κ relative to the μ and δ opioid receptors, respectively. Calculated log BB and CNS (central nervous system) multiparameter optimization (MPO) and low molecular weight values all predict that 12 will penetrate the brain, and pharmacokinetic studies in rats show that 12 does indeed penetrate the brain.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Brain / drug effects*
-
CHO Cells
-
Cricetulus
-
Guanosine 5'-O-(3-Thiotriphosphate) / metabolism
-
Humans
-
Male
-
Narcotic Antagonists / chemistry*
-
Narcotic Antagonists / metabolism
-
Narcotic Antagonists / pharmacology*
-
Radioligand Assay
-
Rats, Sprague-Dawley
-
Receptors, Opioid, delta / antagonists & inhibitors
-
Receptors, Opioid, delta / genetics
-
Receptors, Opioid, delta / metabolism
-
Receptors, Opioid, kappa / antagonists & inhibitors*
-
Receptors, Opioid, kappa / genetics
-
Receptors, Opioid, kappa / metabolism
-
Receptors, Opioid, mu / antagonists & inhibitors
-
Receptors, Opioid, mu / genetics
-
Receptors, Opioid, mu / metabolism
-
Structure-Activity Relationship
-
Tetrahydroisoquinolines / chemistry*
Substances
-
Narcotic Antagonists
-
Receptors, Opioid, delta
-
Receptors, Opioid, kappa
-
Receptors, Opioid, mu
-
Tetrahydroisoquinolines
-
Guanosine 5'-O-(3-Thiotriphosphate)
-
1,2,3,4-tetrahydroisoquinoline